Skip to main content

OrbiMed — Portfolio, Page 11

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

289
Companies
$23.6B
Total invested
$104.0M
Avg. check
23
Industries
Biotechnology 20Health Care 11Pharmaceutical 8Therapeutics 8Medical 6Life Science 3+17 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 241264 of 289
XinThera
August 2021

XinThera is a drug discovery company focused on building small molecule oncology and immunology pipeline.

Biotechnology · San Diego$50.0M Series B
Zentera Therapeutics
August 2021

Zentera Therapeutics is a biopharmaceutical company.

Biotechnology · Shanghai$75.0M Series B
Beijing Yuan Xin
August 2021

Beijing Yuanxin is a technology company that offers an integrated healthcare platform for pharmaceutical distribution and health insurance.

Health Care · Beijing$231.8M Series F
Yuanxin Huibao
August 2021

Yuanxin Huibao is a health insurance technology service provider.

Financial Services · Beijing$231.8M Series F
Zion Pharma
July 2021

Zion Pharma is a drug discovery platform.

Biotechnology · Shanghai$40.0M Series B
Turnstone Biologics
July 2021

Turnstone Biologics is a privately-held clinical stage biotech company.

Biotechnology · La Jolla$80.0M Series D
Imara
July 2021

Imara is provider of novel therapeutics for the people living with sickle cell disease and hemoglobinopathies.

Biopharma · Cambridge$50.0M Post Ipo Equity
NeRRe Therapeutics
July 2021

NeRRe Therapeutics is a biotechnology company that develops clinical and pre-clinical neurokinin receptor antagonists.

Biotechnology · Stevenage$27.6M Series B
Dingdang Kuaiyao
June 2021

Dingdang Kuaiyao is an online-to-offline drug purchasing and delivery platform.

Apps · Beijing$220.0M Private Equity
Splisense
May 2021

Splisense is develops antisense oligonucleotide based therapies to target genetic diseases caused by splicing mutations.

Biotechnology · Jerusalem$28.5M Series B
Magenta Therapeutics
May 2021

Magenta Therapeutics is a new biotechnology company developing therapeutics that unlock the power of stem cell biology.

Biotechnology · Cambridge$86.4M Post Ipo Equity
Theseus Pharmaceuticals
April 2021

Theseus Pharmaceuticals is a technology-based company.

Biotechnology · New York$100.0M Series B
NewMed Medical
March 2021

Medical device supplier based in Shanghai.

Industrial · Shanghai$100.0M Series C
Gemini Therapeutics
February 2021

Gemini Therapeutics focuses on genetically-defined dry age-related macular degeneration (AMD) and associated rare genetic diseases.

Biopharma · Cambridge$95.0M Post Ipo Equity
Passage Bio
January 2021

Passage Bio is a fully integrated gene therapy company developing therapies for the treatment of monogenic central nervous system diseases.

Biotechnology · Philadelphia$154.0M Post Ipo Equity
LogicBio Therapeutics
January 2021

LogicBio develops gene therapy vectors for previously incurable genetic and infectious diseases.

Biotechnology · Foster CityPost Ipo Equity
EmendoBio, Inc.
December 2020

Emendo is a biotechnology company

Biotechnology · New York$250.0M Corporate Round
SAGE Therapeutics
November 2020

SAGE Therapeutics develops and delivers novel medicines for most debilitating and disabling central nervous system disorders.

Biotechnology · Cambridge$650.0M Post Ipo Equity
Turning Point Therapeutics
October 2020

Turning Point Therapeutics is a pharmaceutical company that discovers and develops precision medicines for cancer and other diseases.

Biotechnology · San Diego$460.0M Post Ipo Equity
BioNova Pharma
October 2020

BioNova Pharma biopharmaceutical company that develops treatments for cancer.

Biotechnology · Shanghai$25.0M Series B
Zhaoke Ophthalmology Pharmaceutical
October 2020

Zhaoke Ophthalmology Pharmaceutical is a Pharmaceutical platform.

Biotechnology · Hong Kong$145.0M Series B
BioShin
September 2020

BioShin is a clinical stage biopharmaceutical company.

Biotechnology · Shanghai$60.0M Series A
InventisBio
September 2020

InventisBio is a clinical-stage biotech company dedicated to the research and development of innovative small-molecule drugs.

Biopharma · Shanghai$147.0M Series D
ReViral
August 2020

ReViral is a biotechnology company that develops and offers antiviral therapies for patients.

Biotechnology · Stevenage$44.0M Series C

Where OrbiMed invests

Biotechnology20
Health Care11
Pharmaceutical8
Therapeutics8
Medical6
Life Science3

About OrbiMed's portfolio

How many companies has OrbiMed invested in?

OrbiMed has invested in 289 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does OrbiMed invest in?

OrbiMed's top investment sectors include Biotechnology, Health Care, Pharmaceutical, Therapeutics, Medical. The firm invests across 23 different industry categories.

What is OrbiMed's largest investment?

Among tracked funding rounds, SAGE Therapeutics received $650.0M in a Post Ipo Equity round. OrbiMed's total known invested capital is $23.6B.

What is the average investment size for OrbiMed?

OrbiMed's average investment size is $104.0M across its portfolio of 289 companies.

What are OrbiMed's most recent investments?

Recent OrbiMed portfolio additions include XinThera, Zentera Therapeutics, Beijing Yuan Xin, Yuanxin Huibao, Zion Pharma. These companies were founded in 2020 or later.

Reach the founders behind these 289 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →